Cipemastat
Names | |
---|---|
IUPAC name
(2R,3R)-3-(Cyclopentylmethyl)-N-hydroxy-4-oxo-4-(piperidin-1-yl)-2-[(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)methyl]butanamide | |
Identifiers | |
190648-49-8 | |
3D model (Jmol) | Interactive image |
ChEMBL | ChEMBL115653 |
ChemSpider | 8000097 |
6466 | |
PubChem | 9824350 |
UNII | 02HQ4TYQ60 |
| |
| |
Properties | |
C22H36N4O5 | |
Molar mass | 436.55 g·mol−1 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
verify (what is ?) | |
Infobox references | |
Cipemastat (rINN, also known as Ro 32-3555 and by the tentative trade name Trocade) is a selective inhibitor of matrix metalloproteinase-1 that has been investigated as an anti-arthritis agent.[1] It is being developed by Roche.
References
- ↑ Hemmings F, Farhan M, Rowland J, Banken L, Jain R (2001). "Tolerability and pharmacokinetics of the collagenase-selective inhibitor Trocade in patients with rheumatoid arthritis". Rheumatology (Oxford). 40 (5): 537–43. doi:10.1093/rheumatology/40.5.537. PMID 11371662.
This article is issued from Wikipedia - version of the 5/24/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.